Information for physicians
In Germany, annually more than 200,000 women receive an abnormal Pap test result (Pap III or Pap IIID). They want clarity!
Our newly developed test GynTect® can contribute substantially to the clarification of this important question. GynTect® allows the detection of molecular markers which occur specifically in precancerous or cancer cells. Thus, the test allows to identify among the women with abnormal Pap smear and a positive HPV test result those who may develop or already have a dysplasia that leads to cancer.
New cervical cancer screening:
In several European countries, such as the Netherlands, Germany, HPV-testing may be used in screening of women aged 30 years and older. Women with an HPV infection will then receive clarification by a suitable triage test, if the infection has already led to dysplastic changes with the potential to develop cervical cancer. With GynTect® we provide such a triage test.